Xellia Pharmaceuticals Welcome

Xellia Pharmaceuticals Welcomes VIPs

Xellia Pharmaceuticals Welcomes VIPs from across Ohio as it prepares for Full Scale Manufacturing and Continues to Hire New Talent

Xellia Pharmaceuticals, Copenhagen, Denmark and City of Bedford, Ohio, US, - 14th November 2017 – Xellia Pharmaceuticals (“Xellia”), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, today will welcome local and state dignitaries to its Cleveland site for a reception and tour of the facilities as it enters the final stage of activities to enable full-scale manufacturing.
The visit gives Xellia the opportunity to express its thanks for the ongoing support it is receiving from the City of Bedford and a number of other organizations across the State of Ohio, and also gives visitors the opportunity to see the significant progress that Xellia Cleveland has made.
The visit will be attended by the following VIP guests:

  • Bedford Mayor Stanley Koci
  • Bedford City Council Members
  • Bedford Municipal Judge Brian Melling
  • Southeast Region Chamber of Commerce President Daniel Pocek
  • Cuyahoga County Executive Armond Budish
  • Cuyahoga County Director of Regional Collaboration Eddy Kraus
  • Cuyahoga County Department of Development Director Ted Carter
  • State Representative John E. Barnes, Jr.
  • State Senator Kenneth Yuko

The visit will also be attended by representatives from the following local offices and organizations:

  • BioEnterprise
  • Destination Cleveland
  • Governor John Kasich’s Office of Jobs Ohio
  • Greater Cleveland Partnership
  • Office of U.S. Senator Sherrod Brown
  • Office of U.S. Senator Rob Portman
  • Office of U.S. Congresswoman Marcia Fudge
  • Team Northeast Ohio

Since Xellia acquired the site in 2015, it has been working closely with the US Food and Drug Administration (FDA) to ensure a return to full manufacturing compliance and a timely and controlled start up at the facility. In parallel, Xellia has invested significantly in equipment upgrades and improving facility designs and training a new organization to operate the production suites. At the end of 2016, Xellia passed the FDA inspections, allowing it to commence packaging and distribution of drug products at the Cleveland site.

The site is now going through the final stages required for commencing commercial production of sterile anti-infective injectables, and Xellia anticipates obtaining the final FDA approvals and resuming full manufacturing at the facility during 2018.

Xellia Cleveland has been actively involved in hiring over 100+ staff to date with many of the recent hires coming from the immediate region. Xellia has been able to tap into Ohio’s strong labor base of pharma manufacturing expertize by working closely with local agencies including JobsOhio, Destination Cleveland and the Greater Cleveland Partnership.

Juan-Pablo Gutierrez, Vice President, FDF Manufacturing at Xellia USA said:

“As we look forward to resuming full manufacturing at the Cleveland site next year we are pleased to welcome local dignitaries to witness first-hand the progress that we have made at the site. We are incredibly grateful to the City of Bedford and the state of Ohio as we could not have achieved this progress without their encouragement and support. The US is the most important market for Xellia generating over 50% of total sales in 2016. Further expanding our manufacturing capabilities at our Cleveland site will enable us to address the increasing demand for critical life-saving anti-infectives both locally in the US as well as globally.”

Mayor Stan Koci, City of Bedford, Ohio said:

“We are both excited and honored to have such a dedicated and committed business be part of our community. In the short time Xellia has been in Bedford, they have demonstrated a commitment to development, manufacturing and job creation. Bedford is extremely grateful for their commitment to not only Bedford but Northeast Ohio and we look forward to a long positive relationship”.

Xellia Cleveland is now looking to hire an additional 70+ people over the next few months with job opportunities in the areas of; manufacturing, maintenance mechanics, supply chain, distribution, quality and engineering. There will also be a smaller number of new positions in support functions such as human resources and finance. Xellia Cleveland will be holding a recruitment event for anyone interested in applying for the new roles in December 2017. Prospective employees can find out more about this event, plus the range of roles and exciting opportunities available by visiting Xellia’s Careers page at www.xellia.com.

- Ends -

For more information, please contact:
Xellia Pharmaceuticals

Niels Lynge Agerbæk, General Manager, Xellia Cleveland
Tel: +1 440 359 2050. Niels-Lynge.Agerbak@Xellia.com
Juan-Pablo Gutierrez, Vice President, FDF Manufacturing at Xellia USA Tel: +1 919 327 5490

City of Bedford
Mike Mallis, Manager Tel: +1 440 735 6515 mmallis@bedfordoh.gov.

Instinctif Partners (Xellia Pharmaceuticals International media relations)
Eileen Paul / Ashley Tapp / Melanie Toyne-Sewell Tel: +44 (0) 20 7457 2020
Email: xellia@instinctif.com

About Xellia
Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,500 people.

Xellia has a portfolio of specialty anti-infectives, and is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species.
Many of these are last resort antibiotics, often used when all other treatments have failed. Xellia is also dedicated to providing new anti-infective treatment options by improving the efficacy and delivery, and reducing toxic side effects of existing products. The Company also has early stage R&D programs focused on the discovery and formulation of new chemical entities effective against resistant microbes, with novel modes of action.

Since July 2013, Xellia has been wholly owned by Novo Holdings A/S, the holding company of the Novo Group.
Further information about Xellia can be found at: www.xellia.com.